Listed by the USPTO as VIJAYARAGHAVAN, JAGAMYA NMN
Tech Center 1600 • Art Units: 1632 1633 1637 1651
This examiner grants 61% of resolved cases
VIJAYARAGHAVAN, JAGAMYA NMN works in tech center 1600 and art unit 1632. The profile contains 41 resolved cases, a 61.0% allowance rate, and a median of 1362 days to allowance. The interview lift is 51.0%, indicating a strong positive association between interviews and allowance outcomes in the available record.
The principal company and institutional clients are The Regents of the University of California, Astellas Gene Therapies, Inc., and National Institute of Advanced Industrial Science and Technology. The leading firms are Clark+Elbing LLP, FISH & RICHARDSON P.C. (TC), and OBLON, MCCLELLAND, MAIER & NEUSTADT, L.L.P. The limited case volume makes context important, but the interview measure supports considering examiner interviews as a central prosecution tool.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18547840 | Opsins as Chemosensory Receptors and Related Methods | Non-Final OA | The Regents of the University of California |
| 18298942 | SYNTHETIC TRANSCRIPTION FACTORS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17787161 | 3D TISSUE COMPOSITE AND METHOD OF PRODUCING 3D TISSUE COMPOSITE | Final Rejection | The University Of Tokyo |
| 18863977 | ADAPTATIONS FOR HIGH EFFICIENCY AND ALTERED PAM USAGE WITH TN7-CRISPR-CAS TRANSPOSITION SYSTEMS | Non-Final OA | Cornell University |
| 18729958 | SELECTION METHOD FOR DOMESTIC ANIMAL BREEDING | Non-Final OA | THE PENN STATE RESEARCH FOUNDATION |
| 18246872 | COMPOSITIONS AND METHODS FOR TREATMENT OF FABRY DISEASE | Final Rejection | The Trustees of the University of Pennsylvania |
| 18456269 | Compositions and Methods for Treatment of Myotonic Dystrophy Type 1 with CRISPR/SACAS9 | Non-Final OA | Vertex Pharmaceuticals Incorporated |
| 17796303 | Process for Making Adenoassociated Viral Vectors | Non-Final OA | Oxford University Innovation Limited |
| 18019421 | METHODS OF TREATING CARDIAC DISORDERS AND CONGESTIVE HEART FAILURE AND ADMINISTERING AAV VECTORS | Final Rejection | ASKBIO INC. |
| 17921971 | TARGETED BASE EDITING OF THE USH2A GENE | Non-Final OA | Massachusetts Eye and Ear Infirmary |
| 18467089 | Blood Plasma Product | Final Rejection | Velico Medical, Inc. |
| 18726666 | INTERLOCKING POROUS HYDROGEL BLOCKS | Non-Final OA | Ronawk, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy61.0% of resolved applications examined by Jagamya Nmn Vijayaraghavan were allowed (41 resolved cases), compared with 38.1% across Art Unit 1632 over the last five years.
This examiner's interview lift is +51.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Jagamya Nmn Vijayaraghavan took 1,362 days on average from filing to allowance.
Jagamya Nmn Vijayaraghavan examines applications in Art Unit 1632 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
